converting between glp-1 agonists receptor in the treatment of type 2 diabetes – state-of-the-art glp-1 dose conversion chart I

some head-to-head data suggest slightly higher GI events with Tirzepatide , but discontinuation rates remain modest with slow escalation

Quality varies significantly, and patients need to evaluate potential sources carefully

Volkert D, Beck AM, Cederholm T, Cruz-Jentoft A, Goisser S, Hooper L, et al

Of the 53 100 eligible for inclusion, 2003 were identified as GLP1 RA initiators, and 51 097 were identified as metformin users

GLP-1 RAs in clinical practice The cardioprotective properties of GLP-1 RAs seem to be mediated through CV risk factors modification

Abstract Background: GLP-1 RAs are widely used for T2DM treatment due to their cardiorenal and metabolic benefits